New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...